These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32731087)

  • 1. New V1a receptor antagonist. Part 2. Identification and optimization of triazolobenzazepines.
    Bozó É; Baska F; Lövei K; Szántó G; Domány-Kovács K; Kurkó D; Szondiné Kordás K; Szokoli T; Bata I
    Bioorg Med Chem Lett; 2020 Sep; 30(18):127417. PubMed ID: 32731087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New V1a receptor antagonist. Part 1. Synthesis and SAR development of urea derivatives.
    Szántó G; Makó A; Baska F; Bozó É; Domány-Kovács K; Kurkó D; Cselenyák A; Mohácsi R; Kordás KS; Bata I
    Bioorg Med Chem Lett; 2020 Sep; 30(18):127416. PubMed ID: 32736211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and Characterization of New V
    Szeleczky Z; Szakács Z; Bozó É; Baska F; Vukics K; Lévai S; Temesvári K; Vass E; Béni Z; Krámos B; Magdó I; Szántay C; Kóti J; Domány-Kovács K; Greiner I; Bata I
    J Med Chem; 2021 Jul; 64(14):10445-10468. PubMed ID: 34255509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of spirobenzazepines as potent vasopressin receptor antagonists.
    Xiang MA; Chen RH; Demarest KT; Gunnet J; Look R; Hageman W; Murray WV; Combs DW; Patel M
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2987-9. PubMed ID: 15125974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
    Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
    Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.
    Shimada Y; Taniguchi N; Matsuhisa A; Akane H; Kawano N; Suzuki T; Tobe T; Kakefuda A; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Orita M; Tsunoda T; Tanaka A
    Bioorg Med Chem; 2006 Mar; 14(6):1827-37. PubMed ID: 16290163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Key amino acids of vasopressin V1a receptor responsible for the species difference in the affinity of OPC-21268.
    Shinoura H; Take H; Itoh S; Hirasawa A; Inoue K; Ohno Y; Hashimoto K; Tsujimoto G
    FEBS Lett; 2000 Jan; 466(2-3):255-8. PubMed ID: 10682838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
    Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):63-9. PubMed ID: 9459574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanili de derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilid e derivatives.
    Matsuhisa A; Taniguchi N; Koshio H; Yatsu T; Tanaka A
    Chem Pharm Bull (Tokyo); 2000 Jan; 48(1):21-31. PubMed ID: 10705470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).
    Ślusarz MJ
    Expert Opin Ther Pat; 2015 Jun; 25(6):711-22. PubMed ID: 25776143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[5-(substituted methylidene)-2,3,4,5-tetrahydro-1H-1-ben zoazepine-1-carbonyl]benzanilide and 4'-[5-(substituted methyl)-2,3-dihydro-1H-1-benzoazepine-1- carbonyl]benzanilide derivatives.
    Matsuhisa A; Kikuchi K; Sakamoto K; Yatsu T; Tanaka A
    Chem Pharm Bull (Tokyo); 1999 Mar; 47(3):329-39. PubMed ID: 10212383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nonpeptide V1a and V2 antagonists on blood pressure fast oscillations in conscious rats.
    Japundzic-Zigon N
    Clin Exp Hypertens; 2001 May; 23(4):277-92. PubMed ID: 11349820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte.
    Tahara A; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
    Cardiovasc Res; 1998 Apr; 38(1):198-205. PubMed ID: 9683922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central vasopressin V1A receptor blockade alters patterns of cellular activation and prevents glucocorticoid habituation to repeated restraint stress exposure.
    Gray M; Innala L; Viau V
    Int J Neuropsychopharmacol; 2014 Dec; 17(12):2005-15. PubMed ID: 24913767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of a vasopressin V1 receptor in the isolated human gastric artery.
    Calò G; Rizzi A; Traina L; Regoli D
    Life Sci; 1997; 60(4-5):PL63-8. PubMed ID: 9010490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist.
    Baska F; Bozó É; Szeleczky Z; Szántó G; Vukics K; Szakács Z; Domány-Kovács K; Kurkó D; Vass E; Thán M; Vastag M; Temesvári K; Lévai S; Halász AS; Szondiné Kordás K; Román V; Greiner I; Bata I
    J Med Chem; 2024 Jan; 67(1):643-673. PubMed ID: 38165765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopressin receptor antagonists: a patent summary (2018-2022).
    Baska F; Bozó É; Patócs T
    Expert Opin Ther Pat; 2023; 33(5):385-395. PubMed ID: 37226495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.
    Tahara A; Tsukada J; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
    Pharmacol Res; 2005 Mar; 51(3):275-81. PubMed ID: 15661579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-peptide arginine-vasopressin antagonists: the vaptans.
    Decaux G; Soupart A; Vassart G
    Lancet; 2008 May; 371(9624):1624-32. PubMed ID: 18468546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacology of conivaptan hydrochloride (YM087), a novel vasopressin V1A/V2 receptor antagonist].
    Yatsu T; Tomura Y; Tahara A; Wada K; Kusayama T; Tsukada J; Tanaka A; Iizumi Y; Honda K
    Nihon Yakurigaku Zasshi; 1999 Oct; 114 Suppl 1():113P-117P. PubMed ID: 10629866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.